Patrick Keran
Nessuna posizione attualmente
Patrimonio netto: 439 198 $ in data 30/06/2024
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Shweta Singh Maniar | F | 40 | 3 anni | |
| John Henneman | M | 62 | 9 anni | |
| Wayne Burris | M | 69 | 3 anni | |
| Joseph Klein | M | 62 | 19 anni | |
| Angela Steinway | F | - | 3 anni | |
| Tyler P. Lipschultz | M | 57 | 1 anni | |
| William Rhoda | M | - | 8 anni | |
| Dennis L. Cirino | M | 54 | 6 anni | |
| Matt Buck | M | - | 19 anni | |
| Sarah Hollis Winkler | F | 49 | 2 anni | |
| Beau Standish | M | - | 1 anni | |
| Haitao Liu | M | - | 2 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Jon Serbousek | M | 63 | 4 anni | |
| John Bostjancic | M | 53 | 8 anni | |
| Evan Levine | M | 59 |
Mast Therapeutics, Inc.
 Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | 6 anni |
| Stuart Essig | M | 62 | 9 anni | |
| Keith Valentine | M | 56 | - | |
| Brandi Roberts | F | 50 |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | 6 anni |
| John Sicard | M | 61 | 5 anni | |
| Thomas West | M | 60 | 2 anni | |
| Shana C. Hood | F | - |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | - |
| Douglas Rice | M | 58 | 9 anni | |
| Lilly Marks | F | 76 | 8 anni | |
| Howard C. Dittrich | M | 71 |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | 3 anni |
| Ted Love | M | 65 |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | 1 anni |
| Keith Bradley | M | 79 | 8 anni | |
| David Ramsay | M | 59 |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | 6 anni |
| Gregory P. Hanson | M | 77 |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | 2 anni |
| Kimberly Commins-Tzoumakas | F | 56 | 2 anni | |
| Jack Lief | M | 78 |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | 9 anni |
| Lewis J. Shuster | M | 68 |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | 5 anni |
| Colin Smith | M | - | 3 anni | |
| Laetitia Cousin | F | 48 | 7 anni | |
| Carrie E. Carlander McQueen | F | 53 |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | - |
| Renee Gaeta | F | 43 | - | |
| Eric Rowinsky | M | 67 |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | - |
| Cheryl Blanchard | M | 59 | 4 anni | |
| Ethel M. Koczon | F | - | 5 anni | |
| Claire S. Padgett | M | - |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | 6 anni |
| John C. Arthur | M | 58 |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | 3 anni |
| John Clapacs | M | - |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | - |
| Edwin L. Parsley | M | 63 |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | - |
| Odysseas Kostas | M | 49 |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | 1 anni |
| Brian Baker | M | 57 | 3 anni | |
| Karen Potts | M | 61 | 3 anni | |
| Daniel Ripley | M | 63 | 6 anni | |
| Neil Abdollahian | M | 51 | 1 anni | |
| Mark Bagnall | M | 67 |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | 5 anni |
| Jose Hechavarria | M | - |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | - |
| Robert Emanuele | M | 69 |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | 5 anni |
| Keith Meister | M | 51 |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | 1 anni |
| Richard DiMarchi | M | 71 | 7 anni | |
| Robert A. Daniel | M | - |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | - |
| Santosh Vetticaden | M | 65 |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | 2 anni |
| Gregory Gorgas | M | 61 |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | 6 anni |
| Dana Lee | M | 60 |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | 1 anni |
| James A. Merritt | M | 72 |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | 2 anni |
| Michele L. Yelmene | F | 60 |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | 2 anni |
| Christopher F. O. Gabrieli | M | 64 | 17 anni | |
| Alexander Denner | M | 54 |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | 3 anni |
| M. Ross Johnson | M | 79 |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | 5 anni |
| Mark E. Erwin | M | 59 |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | - |
| Jennifer Giottonini Cayer | F | - | 1 anni | |
| Jeffrey Black | M | 55 | 2 anni | |
| Michael Withers | M | 55 | 6 anni |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Stati Uniti | 65 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Patrick Keran
- Contatti personali
